NEJM· @NEJM · X·· 10 天前精选AI 评分75
AI 导读
在合并动脉粥样硬化性心血管疾病、慢性肾脏病和炎症的患者中,ziltivekimab 降低了白细胞介素-6 水平,但心血管事件并未少于安慰剂。ZEUS 试验完整结果已在 #ScientificSessions26 公布,全文见 https://nej.md/3UCOqQC。
推荐理由
ZEUS 试验显示 ziltivekimab 虽降低 IL-6 水平,但未减少心血管事件,为抗炎治疗路径提供了阴性对照。
正文
Presented at #ScientificSessions26:
In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, ziltivekimab decreased interleukin-6 levels but did not result in fewer cardiovascular events than placebo. Full ZEUS trial results: https://nej.md/3UCOqQC
@AHAScience
来源:NEJM · x.com